Table 1 Baseline patient characteristics
Analysed patients (n = 103)Responders (n = 70)Non-responders (n = 33)p Value
Demographics:
Age (years)55 (13)54 (13)56 (12)0.40
Female (%)71 (69)51 (73)20 (61)0.21
Disease status:
Disease duration (months)125 (110)123 (111)130 (110)0.80
Erosive disease (%)79 (77)57 (81)22 (67)0.10
RF positive (%)77 (75)57 (81)20 (61)0.02
Anti-CCP positive (%)78 (76)57 (81)13 (39)0.08
DAS285.9 (1.1)6.0 (1.0)5.6 (1.2)0.07
Patients global score (0–100 mm)60 (22)62 (21)56 (23)0.23
ESR (mm/h)34 (24)36 (23)29 (25)0.16
CRP (mg/dl)22 (28)24 (26)19 (30)0.36
Drug treatments:
Previous DMARDs2.2 (1.5)2.1 (1.4)2.4 (1.6)0.42
Methotrexate (mg/week)18.8 (8.5)19.5 (8.2)17.1 (8.9)0.18
Receiving corticosteroids (%)28 (27)22 (31)6 (18)0.22
Receiving NSAIDs (%)52 (50)35 (50)17 (52)0.89
  • Mean (SD), median and interquartile range (IQR) or percentages are shown. p Values <0.05 (two-sided) were considered significant.

  • CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-inflammatory drug; RF, rheumatoid factor.